PCM
MRSN

Prelude Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Prelude Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,054
Closed -$73.4K – 1429
2024
Q4 		$73.4K Sell
2,054
-12,535
-86% -$648K 0.01% 1126
2024
Q3 		$689K Buy
+14,589
New +$644K 0.05% 503
2020
Q4 		– Sell
-18
Closed -$8K – 1851
2020
Q3 		$8K Buy
+18
New +$9.1K ﹤0.01% 1490
2018
Q2 		– Sell
-90
Closed -$36K – 1876
2018
Q1 		$36K Buy
90
+86
+2,150% +$34K ﹤0.01% 1160
2017
Q4 		$2K Buy
+4
New +$1.74K ﹤0.01% 1300

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return